

Date : - |

To
Neuland Laboratories Limited
11th Floor (5th Office Level), Phoenix IVY Building,
Plot No.573A-III, Road No. 82,
Jubilee Hills, Hyderabad- 500033

Subject: Declaration for claiming tax treaty benefits on dividend income for the period 1 April 2020- 31 March 2021

Ref: Folio Number / DP Id-Client Id – Mention all the account details

We, **<shareholder name>**, hereby confirm the following:

1. We are a **<insert legal entity status such as Non-Resident Individual/ Firm/ Association of persons/ Body of Individual/ Trust/ foreign company>** having registered address at **<insert registered address>** bearing Permanent Account Number as **<insert Permanent Account Number>** |
2. The Tax Identification Number / Unique Identification Number as issued by the Government of **<name of the country>** is |_____|
3. We are tax resident of **<name of the country>** | in accordance with the provisions of Article 4 of the Double Taxation Avoidance Agreement between India and **<insert country>** (“treaty”)The Tax Residency Certificate issued by _____ is attached herewith. We further confirm that we are entitled to claim the benefits of the treaty between the two countries, taking into consideration the Multilateral Instrument (“MLI”) signed by both the countries, including, but not limited to, satisfaction of the “Principal Purpose Test” provided in such MLI.
4. We do not/ will not have any “Permanent Establishment” in India as envisaged under Articles 5 of the treaty during the period 1 April 2020 to 31 March 2021.
5. We are the beneficial owner of the dividends declared, distributed or paid by Neuland Laboratories Limited to us. Specifically, we confirm that we will have exclusive possession and control over the dividend received, and that we have the absolute discretion to utilise the dividend received without being constrained by any contractual, legal or other arrangement to pass on such dividends to any other person.
6. We hereby confirm that we do/ will not have a place of effective management, during the period 1 April 2020 to 31 March 2021, in India and none of the key management and commercial decisions for the conduct of business in substance are/ will be made in India.
7. Our e-mail id |_____| and contact number is |_____| respectively.

We hereby certify that declarations made above are true and *bona fide*. In case of any change in the declaration on any of the above aspects, we undertake to promptly intimate you of the said event.

We also undertake to provide all additional documents/ information, as may be prescribed/required by the Indian Revenue authorities, in order to substantiate any of the above aspects.

We further agree to indemnify, defend and hold good Neuland Laboratories Limited from any liability (including towards tax, interest and penalty) that may arise, or may be asserted against Neuland Laboratories Limited with respect to the availability of treaty benefits (including under the MLI) in respect of such dividends.

Yours sincerely,

For |<*shareholder name*>|

Authorised Signatory

Name : |<< Name of person signing declaration>>|

Designation : |<< Designation of person signing declaration>>|

Note: In cases of non-individual shareholders, declaration to be printed on the letterhead